Enacademic πŸŽ“Analogindex
54 subscribers
77.4K photos
2 videos
249K links
Download Telegram
Stock Market Today: Stocks mixed amid earnings rush, bulls cheer new highs

Check back for updates throughout the trading day U.S. equity futures were mixed in early Tuesday trading, following on from the second consecutive record close for the S&P 500, as investors continue to bet that a solid earnings season and fading inflation will guide the domestic economy to a soft landing this year. Stocks ended higher again yesterday, with the Dow topping the 38,000-point mark for the first time and the S&P 500 notching its second record close. The figures were posted even in the face of a muted gain for the so-called Magnificent 7 tech stocks and a nudge higher in Treasury yields. Investors are now likely to focus on a busy corporate earnings calendar over the next three sessions. Netflix (NFLX) - Get Free Report is slated to update investors after the close of trading and Johnson & Johnson, General Electric, 3M and Procter & Gamble are reporting before the bell. MANDEL NGAN/AFP via Getty Images GE shares slipped after the industrials giant topped Wall Street forecasts for fourth-quarter profit but forecast muted free-cash-flow and earnings to start the new year. Johnson & Johnson's profit outlook was also stable, with the pharma giant reiterating its 2024 outlook following a stronger-than-expected fourth-quarter update. United Airlines (UAL) - Get Free Report, which reported after the close of trading last night, was the standout premarket mover. The stock surged more than 6% after the carrier offset an expected hit from Boeing (BA) - Get Free Report aircraft delays with an upbeat profit outlook for 2024 of between $9 and $11 a share. Overall, analysts see collective fourth-quarter S&P 500 profits rising around 4.5% from the same period in 2022 to a share-weighted $454.2 billion. First-quarter profits are expected to rise 6.6% to $468 billion. In other markets, benchmark 10-year Treasury note yields were holding steady at 4.132% in early New York trading while 2-year notes were pegged at 4.408%. That's ahead of a $60 billion auction of new paper later today, the first of three coupon sales this week that will raise around $162 billion. The U.S. dollar index, which tracks the greenback against a basket of six global currencies, was marked 0.1% higher at 103.439. On Wall Street, stock futures suggest a muted open, with the S&P 500 called 1 point higher and the Dow Jones Industrial Average indicating a pullback of around 64 points. The tech-focused Nasdaq, meanwhile, is called 24 points higher. In Europe, the Stoxx 600 was marked 0.2% lower in early Frankfurt dealing, with Britain's FTSE 100 down 0.12% and closely tracking U.S. equity futures. Overnight in Asia, the Bank of Japan held its key policy rate steady at -0.1%, while maintaining its overall tenor of ultra-loose policy, as it lowered inflation forecasts for the coming year. The Nikkei 225, which closed at a 34-year high on Monday, ended the session 0.06% lower at 36,517.57 points. The broader MSCI ex-Japan index slipped 0.06% into the close of trading.Related: Veteran fund manager picks favorite stocks for 2024
Read more...
*Π§Ρ‚ΠΎ Ρ‚Π°ΠΊΠΎΠ΅ эпизиотомия ΠΈ ΠΊΠ°ΠΊ послС Π½Π΅Ρ‘ Π²ΠΎΡΡΡ‚Π°Π½ΠΎΠ²ΠΈΡ‚ΡŒΡΡ*

ΠžΠΏΠ΅Ρ€Π°Ρ†ΠΈΡ ΠΎΠ±Π»Π΅Π³Ρ‡Π°Π΅Ρ‚ Ρ€ΠΎΠ΄Ρ‹, Π½ΠΎ ΠΎΠ½Π° Π½ΡƒΠΆΠ½Π° Π½Π΅ всСм.
[Read more...](https://lifehacker.ru/chto-takoe-epiziotomiya/)
*What are you not embarrassed to admit?*

52m, and I’m afraid of the dark. submitted by /u/jonniebaby2000 to r/RandomThoughts [link] [comments]
[Read more...](https://www.reddit.com/r/RandomThoughts/comments/19dd0wc/what_are_you_not_embarrassed_to_admit/)
What are you not embarrassed to admit?

52m, and I’m afraid of the dark. submitted by /u/jonniebaby2000 to r/RandomThoughts link comments
Read more...
*Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings*

Updated at 7:16 AM EST Johnson & Johnson (JNJ) - Get Free Report posted modestly better-than-expected fourth-quarter earnings Tuesday, while reiterating its full-year profit forecast, thanks to solid sales for its psoriasis and cancer therapies. Adjusted earnings for the three months ended in December were $2.29 a share, down 2.6% from the same period in 2022 but a penny ahead of the Wall Street consensus forecast. Related: Humana plunges on major health insurance warning; UnitedHealth, CVS tumble Group revenue, Johnson & Johnson said, slipped 9.7% to $21.4 billion, exceeding analysts' estimates of a $21 billion tally. Pharmaceutical sales were up 5.4% to $13.72 billion while Medtech sales jumped 13% to $7.67 billion. Consumer health sales were spun off to Kenvue, the group's stand-alone entity, in early 2023. Johnson & Johnson reiterated that 2024 earnings should come in around $10.55 to $10.75 a share. Operational sales are expected to rise 5% to 6%, suggesting a tally between $88.2 billion and $89 billion. The new figures exclude the impact of Kenvue.J&J CEO: Entering '24 in 'position of strength' "Johnson & Johnson’s full-year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said CEO Joaquin Duato. β€œWe have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.” Johnson & Johnson shares were marked 0.23% lower in premarket trading immediately following the earnings release to indicate an opening bell price of $162.10 each, a move that would extend the stock's six-month decline to around 5.3%. Earlier this month, Johnson & Johnson said it would pay $28 a share in cash for cancer-drug specialists Ambx Biopharma (AMAM) - Get Free Report, a deal that values the La Jolla, Calif., biotech at around $2 billion. Ambrx focuses on so-called antibody drug conjugates, which attack cancer cells from the outside without damaging healthy tissues in the rest of the body. The group has used its techniques to target breast cancer and prostate cancer in recent clinical trials and has won fast-track designation for its ARX517 prostate therapy from the U.S. Food and Drug Administration.Related: Veteran fund manager picks favorite stocks for 2024
[Read more...](https://www.thestreet.com/investing/stocks/johnson-johnson-holds-2024-profit-forecast-steady-after-solid-q4-earnings)
*Verizon leaps as key factor in outlook adds fuel to Q4 earnings beat*

Verizon (VZ) - Get Free Report posted better-than-expected fourth quarter earnings Tuesday, while forecasting solid 2024 profits thanks in part to its flexible wireless plans and promotions linked to Apple's (AAPL) - Get Free Report new iPhone 15. Adjusted non-GAAP earnings for the three months ended in December were $1.08 a share, down 9.2% from the same period in 2022 but topping the Wall Street consensus forecast of $1.07 per share. Related: Iconic retailer rejects multibillion-dollar takeover bid Group revenue, Verizon said, slipped 0.4% from a year earlier to $35.1 billion, just ahead of analysts' estimates of a $34.58 billion tally. Verzion's postpaid additions for the quarter were pegged at 446,000, the highest in nearly two years and double analysts' estimates. That's thanks in part to hybrid plans that include streaming subscriptions such as Netflix (NFLX) - Get Free Report and Max. (WBD) - Get Free Report Looking into the coming year, Verizon sees wireless revenue growing 2% to 3.5%. Adjusted earnings are estimated in the region of $4.50 to $4.70 per share, compared with an LSEG forecast of around $4.59 per share.Verizon CEO: Balance of growth, profitability "After delivering continuous improvement throughout 2023, we ended the year strong and continue to pursue the right balance of growth and profitability," Chief Executive Hans Vestberg said in a statement. Shutterstock The year "2023 was a year of change. We have the right assets and the best team in place and are well-positioned for growth in 2024." Verizon shares were marked 1.6% higher in premarket trading immediately following the earnings release to indicate an opening bell price of $40.20 each. Technology:AI takes this stock to record; investors look past Magnificent 7 Amazon plan to paywall a popular product hits a roadblock AI stock soars on new guidance (it's not Nvidia!) Last November, the group named Tony Skiadas as full-time chief financial office. Vestberg said the move positioned the company veteran "to steer us through the current economic volatility and our industry's changing landscape." Verizon's ongoing deployment of its 5G network, built in part on the $53 billion purchase of new C-Band spectrum from the U.S. government, remains a key plank in the group's growth prospects Related: Veteran fund manager picks favorite stocks for 2024
[Read more...](https://www.thestreet.com/investing/stocks/verizon-leaps-as-2024-subscriber-outlook-adds-fuel-to-q4-earnings-beat)
Johnson & Johnson holds 2024 profit forecast steady after solid Q4 earnings

Updated at 7:16 AM EST Johnson & Johnson (JNJ) - Get Free Report posted modestly better-than-expected fourth-quarter earnings Tuesday, while reiterating its full-year profit forecast, thanks to solid sales for its psoriasis and cancer therapies. Adjusted earnings for the three months ended in December were $2.29 a share, down 2.6% from the same period in 2022 but a penny ahead of the Wall Street consensus forecast. Related: Humana plunges on major health insurance warning; UnitedHealth, CVS tumble Group revenue, Johnson & Johnson said, slipped 9.7% to $21.4 billion, exceeding analysts' estimates of a $21 billion tally. Pharmaceutical sales were up 5.4% to $13.72 billion while Medtech sales jumped 13% to $7.67 billion. Consumer health sales were spun off to Kenvue, the group's stand-alone entity, in early 2023. Johnson & Johnson reiterated that 2024 earnings should come in around $10.55 to $10.75 a share. Operational sales are expected to rise 5% to 6%, suggesting a tally between $88.2 billion and $89 billion. The new figures exclude the impact of Kenvue.J&J CEO: Entering '24 in 'position of strength' "Johnson & Johnson’s full-year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said CEO Joaquin Duato. β€œWe have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.” Johnson & Johnson shares were marked 0.23% lower in premarket trading immediately following the earnings release to indicate an opening bell price of $162.10 each, a move that would extend the stock's six-month decline to around 5.3%. Earlier this month, Johnson & Johnson said it would pay $28 a share in cash for cancer-drug specialists Ambx Biopharma (AMAM) - Get Free Report, a deal that values the La Jolla, Calif., biotech at around $2 billion. Ambrx focuses on so-called antibody drug conjugates, which attack cancer cells from the outside without damaging healthy tissues in the rest of the body. The group has used its techniques to target breast cancer and prostate cancer in recent clinical trials and has won fast-track designation for its ARX517 prostate therapy from the U.S. Food and Drug Administration.Related: Veteran fund manager picks favorite stocks for 2024
Read more...
Verizon leaps as key factor in outlook adds fuel to Q4 earnings beat

Verizon (VZ) - Get Free Report posted better-than-expected fourth quarter earnings Tuesday, while forecasting solid 2024 profits thanks in part to its flexible wireless plans and promotions linked to Apple's (AAPL) - Get Free Report new iPhone 15. Adjusted non-GAAP earnings for the three months ended in December were $1.08 a share, down 9.2% from the same period in 2022 but topping the Wall Street consensus forecast of $1.07 per share. Related: Iconic retailer rejects multibillion-dollar takeover bid Group revenue, Verizon said, slipped 0.4% from a year earlier to $35.1 billion, just ahead of analysts' estimates of a $34.58 billion tally. Verzion's postpaid additions for the quarter were pegged at 446,000, the highest in nearly two years and double analysts' estimates. That's thanks in part to hybrid plans that include streaming subscriptions such as Netflix (NFLX) - Get Free Report and Max. (WBD) - Get Free Report Looking into the coming year, Verizon sees wireless revenue growing 2% to 3.5%. Adjusted earnings are estimated in the region of $4.50 to $4.70 per share, compared with an LSEG forecast of around $4.59 per share.Verizon CEO: Balance of growth, profitability "After delivering continuous improvement throughout 2023, we ended the year strong and continue to pursue the right balance of growth and profitability," Chief Executive Hans Vestberg said in a statement. Shutterstock The year "2023 was a year of change. We have the right assets and the best team in place and are well-positioned for growth in 2024." Verizon shares were marked 1.6% higher in premarket trading immediately following the earnings release to indicate an opening bell price of $40.20 each. Technology:AI takes this stock to record; investors look past Magnificent 7 Amazon plan to paywall a popular product hits a roadblock AI stock soars on new guidance (it's not Nvidia!) Last November, the group named Tony Skiadas as full-time chief financial office. Vestberg said the move positioned the company veteran "to steer us through the current economic volatility and our industry's changing landscape." Verizon's ongoing deployment of its 5G network, built in part on the $53 billion purchase of new C-Band spectrum from the U.S. government, remains a key plank in the group's growth prospects Related: Veteran fund manager picks favorite stocks for 2024
Read more...
*ΠžΠ±Π·ΠΎΡ€ Huawei MatePad Pro 13.2β€³ β€” флагманского ΠΏΠ»Π°Π½ΡˆΠ΅Ρ‚Π° Π½Π° Π·Π°ΠΌΠ΅Π½Ρƒ Π½ΠΎΡƒΡ‚Π±ΡƒΠΊΡƒ*

Π’ ΠΏΠ°Ρ€Π΅ с ΠΊΠ»Π°Π²ΠΈΠ°Ρ‚ΡƒΡ€ΠΎΠΉ Π³Π°Π΄ΠΆΠ΅Ρ‚ прСвращаСтся Π² ΡƒΠ΄ΠΎΠ±Π½Ρ‹ΠΉ Ρ€Π°Π±ΠΎΡ‡ΠΈΠΉ инструмСнт, Π° Π²ΠΎΡ‚ для ΠΈΠ³Ρ€ ΠΌΠΎΠΆΠ΅Ρ‚ Π½Π΅ ΠΏΠΎΠ΄ΠΎΠΉΡ‚ΠΈ.
[Read more...](https://lifehacker.ru/obzor-huawei-matepad-pro-13-2/)